エピジェネティクス医薬品と診断技術の世界市場レポート 2025年

エピジェネティクス医薬品と診断技術市場規模は、今後数年間で飛躍的な成長が見込まれます。2029年にはCAGR21.4％で410億3,000万米ドルに成長します。予測期間の成長は、神経疾患の有病率の上昇、炎症性疾患の有病率の上昇、慢性疾患の有病率の上昇、個別化医療に対する需要の高まり、エピジェネティック診断に対する認識と採用の高まりに起因しています。予測期間における主な動向には、エピジェネティクスに基づく個別化治療の革新、エピジェノミクスと人工知能の統合、研究および臨床におけるマルチオミクスアプローチの革新、先端技術、診断技術の革新などが含まれます。

がんの有病率の上昇は、エピジェネティクス医薬品と診断技術市場の成長を促進すると予想されます。がんは、体の他の部分に浸潤または転移する可能性のある異常な細胞増殖を特徴とするさまざまな疾患を包含します。この有病率の増加は、人口の高齢化、ライフスタイルの変化、環境汚染物質、遺伝的素因、診断技術の進歩などの要因に影響されています。エピジェネティック医薬品と診断技術は、遺伝子発現を標的とし修正することで、早期発見を容易にし、個別化された治療アプローチを可能にすることで、増加するがん罹患率に対処する上で重要な役割を果たしています。例えば、2024年7月、オーストラリアの政府機関であるオーストラリア保健福祉研究所は、オーストラリアで診断されたがん患者数が2021年の15万6,781人から2022年には16万570人に増加したと報告しました。その結果、がんの有病率の増加がエピジェネティクス医薬品と診断技術市場の拡大を牽引しています。

エピジェネティクス医薬品と診断技術市場の主要企業は、疾患検出の精度と有効性を高め、個別化治療戦略を洗練させ、さまざまな疾患にわたる遺伝子制御の理解を深めるために、DNAメチル化解析などの革新的技術の創出に注力しています。DNAメチル化解析では、DNAのシトシン塩基にメチル基が付加される化学修飾であるDNAメチル化のパターンを研究します。例えば、2023年8月、米国のバイオテクノロジー企業であるウォッチメーカー・ジェノミクス社は、米国の分子診断会社であるイグザクト・サイエンシズ社と提携し、TET-assisted pyridine borane sequencing（TAPS）と呼ばれる新規DNAメチル化解析技術を開発・商業化しました。この提携は、DNA修飾酵素のエンジニアリングにおけるWatchmaker社の専門知識を活用し、TAPS化学を強化することで、がんのスクリーニングと診断能力を向上させることを目的としています。この提携は、がんの早期発見や、DNAメチル化パターンが健康状態のバイオマーカーとして機能するリキッドバイオプシーによる微小残存病変（MRD）のモニタリングに極めて重要です。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、新型コロナウイルス感染症、そして景気回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界エピジェネティクス医薬品と診断技術 PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界のエピジェネティクス医薬品と診断技術市場：成長率分析
• 世界のエピジェネティクス医薬品と診断技術市場の実績：規模と成長, 2019-2024
• 世界のエピジェネティクス医薬品と診断技術市場の予測：規模と成長, 2024-2029, 2034F
• 世界エピジェネティクス医薬品と診断技術総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のエピジェネティクス医薬品と診断技術市場：技術別、実績と予測, 2019-2024, 2024-2029F, 2034F
• デオキシリボ核酸（DNA）のメチル化
• ヒストンのメチル化
• ヒストンのアセチル化
• 大きな非コードリボ核酸（RNA）
• マイクロRNAの修飾
• クロマチン構造
• 世界のエピジェネティクス医薬品と診断技術市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 腫瘍学
• 固形腫瘍
• 液体腫瘍
• 非腫瘍学
• 炎症性疾患
• 代謝性疾患
• 感染症
• 心血管疾患
• その他の用途
• 世界のエピジェネティクス医薬品と診断技術市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院と診療所
• 診断センター
• その他のエンドユーザー
• 世界のエピジェネティクス医薬品と診断技術市場デオキシリボ核酸（DNA）メチル化の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• メチル化阻害剤
• メチル化検出キット
• メチル化プロファイリング技術
• バイサルファイトシーケンシング
• 世界のエピジェネティクス医薬品と診断技術市場ヒストンメチル化のサブセグメンテーション（タイプ別）、実績と予測, 2019-2024, 2024-2029F, 2034F
• ヒストンメチルトランスフェラーゼ阻害剤
• ヒストン脱メチル化酵素阻害剤
• ヒストンメチル化アッセイ
• クロマチン免疫沈降（ChIP）技術
• 世界のエピジェネティクス医薬品と診断技術市場ヒストンのアセチル化のサブセグメンテーション（タイプ別）、実績と予測, 2019-2024, 2024-2029F, 2034F
• ヒストンアセチルトランスフェラーゼ阻害剤
• ヒストン脱アセチル化酵素阻害剤（HDACi）
• アセチル化検出キット
• アセチル化のウェスタンブロッティング
• 世界のエピジェネティクス医薬品と診断技術市場、大きな非コードリボ核酸（RNA）の種類によるサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• lncRNA発現プロファイリング
• lncRNA変調技術
• lncRNA検出キット
• lncRNA解析のためのバイオインフォマティクスツール
• 世界のエピジェネティクス医薬品と診断技術市場マイクロRNA修飾のサブセグメンテーション（タイプ別）、実績と予測, 2019-2024, 2024-2029F, 2034F
• マイクロRNA模倣物
• マイクロRNA阻害剤
• マイクロRNA発現解析
• マイクロRNA検出アッセイ
• 世界のエピジェネティクス医薬品と診断技術市場クロマチン構造のサブセグメンテーション（タイプ別）、実績と予測, 2019-2024, 2024-2029F, 2034F
• クロマチンリモデリング剤
• クロマチンアクセシビリティアッセイ
• 3Dクロマチンアーキテクチャ技術
• 核イメージング技術

第7章 地域別・国別分析

• 世界のエピジェネティクス医薬品と診断技術市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のエピジェネティクス医薬品と診断技術市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• エピジェネティクス医薬品と診断技術市場：競合情勢
• エピジェネティクス医薬品と診断技術市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Thermo Fisher Scientific Inc.
• AstraZeneca PLC
• Illumina Inc.
• QIAGEN NV
• Exact Sciences Corporation
• Abcam PLC
• Syndax Pharmaceuticals Inc.
• Astex Pharmaceuticals Inc.
• Diagenode LLC
• Cisbio Bioassays
• 4SC AG
• Verogen Inc.
• Watchmaker Genomics Inc.
• Oryzon Genomics SA
• Cell Centric Ltd.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• エピジェネティクス医薬品と診断技術市場2029：新たな機会を提供する国
• エピジェネティクス医薬品と診断技術市場2029：新たな機会を提供するセグメント
• エピジェネティクス医薬品と診断技術市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Epigenetics drugs and diagnostic technologies refer to therapeutic and diagnostic approaches that target and analyze the epigenetic mechanisms regulating gene expression without altering the underlying DNA sequence. These technologies are focused on modifying or assessing the chemical modifications to DNA and histones that influence gene activity, offering potential treatments for various diseases and advanced diagnostic tools.

The main technologies of epigenetics drugs and diagnostic technologies are deoxyribonucleic acid (DNA) methylation, histone methylation, histone acetylation, large noncoding ribonucleic acid (RNA), microRNA modification, chromatin structures. Deoxyribonucleic acid (DNA) methylation involves adding a methyl group to the DNA molecule, typically at cytosine bases. These are used in various applications such as oncology, solid tumors, liquid tumors, nononcology, inflammatory diseases, metabolic diseases, infectious diseases, cardiovascular diseases, and others, and also by various end-users such as hospitals and clinics, diagnostic centers, and others.

The epigenetics drugs and diagnostic technologies market research report is one of a series of new reports from The Business Research Company that provides epigenetics drugs and diagnostic technologies market statistics, including epigenetics drugs and diagnostic technologies industry global market size, regional shares, competitors with an epigenetics drugs and diagnostic technologies market share, detailed epigenetics drugs and diagnostic technologies market segments, market trends, and opportunities, and any further data you may need to thrive in the epigenetics drugs and diagnostic technologies industry. This epigenetics drugs and diagnostic technology research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The epigenetics drugs and diagnostic technologies market size has grown exponentially in recent years. It will grow from $15.49 $ billion in 2024 to $18.86 $ billion in 2025 at a compound annual growth rate (CAGR) of 21.8%. The growth in the historic period can be attributed to increasing understanding of epigenetic mechanisms, the development of genome-wide association studies (GWAS), increasing demand for healthcare, increasing geriatric populations, and increasing prevalence of cancer.

The epigenetics drugs and diagnostic technologies market size is expected to see exponential growth in the next few years. It will grow to $41.03 $ billion in 2029 at a compound annual growth rate (CAGR) of 21.4%. The growth in the forecast period can be attributed to rising prevalence of neurological diseases, increasing prevalence of inflammatory disorders, rising prevalence of chronic diseases, growing demand for personalized medicine and increasing awareness and adoption of epigenetic diagnostics. Major trends in the forecast period include innovations in epigenetic-based personalized therapies, integration of epigenomics with artificial intelligence, innovations in multi-omics approaches in research and clinical practice, advanced technologies, and innovating diagnostic techniques.

The rising prevalence of cancer is expected to drive the growth of the epigenetics drugs and diagnostic technologies market. Cancer encompasses a range of diseases characterized by abnormal cell growth that can invade or spread to other parts of the body. This increasing prevalence is influenced by factors such as aging populations, lifestyle changes, environmental pollutants, genetic predispositions, and advancements in diagnostic techniques. Epigenetic drugs and diagnostic technologies play a crucial role in addressing the rising incidence of cancer by targeting and modifying gene expression, facilitating early detection, and enabling personalized treatment approaches. For example, in July 2024, the Australian Institute of Health and Welfare, an Australian government agency, reported that the number of cancer cases diagnosed in Australia rose from 156,781 in 2021 to 160,570 in 2022. Consequently, the growing prevalence of cancer is driving the expansion of the epigenetics drugs and diagnostic technologies market.

Major companies in the epigenetics drugs and diagnostic technologies market are concentrating on creating innovative technologies, such as DNA methylation analysis, to boost the precision and effectiveness of disease detection, refine personalized treatment strategies, and deepen our understanding of gene regulation across various diseases. DNA methylation analysis involves studying the patterns of DNA methylation, which is a chemical modification where a methyl group is added to the cytosine base of DNA. For example, in August 2023, Watchmaker Genomics Inc., a US-based biotechnology firm, teamed up with Exact Sciences Corp., a US-based molecular diagnostics company, to develop and commercialize a novel DNA methylation analysis technology called TET-assisted pyridine borane sequencing (TAPS). This partnership aims to improve cancer screening and diagnostic capabilities by utilizing Watchmaker's expertise in engineering DNA-modifying enzymes to enhance TAPS chemistry. This collaboration is crucial for early cancer detection and monitoring minimal residual disease (MRD) through liquid biopsies, where DNA methylation patterns act as biomarkers for health status.

In January 2022, Active Motif Incorporated, a US-based firm specializing in epigenetics and chromatin biology, acquired Amaryllis Nucleics for an undisclosed sum. This acquisition enables Active Motif to provide a more integrated approach to gene expression analysis by combining their expertise in chromatin biology and epigenetics with Amaryllis Nucleics' RNASeq technology. Amaryllis Nucleics, also based in the US, specializes in epigenetics drugs and diagnostic technologies.

Major companies operating in the epigenetics drugs and diagnostic technologies market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co Inc., Novartis AG, Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., AstraZeneca PLC, Illumina Inc., QIAGEN NV, Exact Sciences Corporation, Abcam PLC, Syndax Pharmaceuticals Inc., Astex Pharmaceuticals Inc., Diagenode LLC, Cisbio Bioassays, 4SC AG, Verogen Inc., Watchmaker Genomics Inc., Oryzon Genomics SA, Cell Centric Ltd., Epiaxis Therapeutics

North America was the largest region in the epigenetics drugs and diagnostic technologies market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the epigenetics drugs and diagnostic technologies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the epigenetics drugs and diagnostic technologies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The epigenetics drugs and diagnostic technologies market consists of revenues earned by entities by providing DNA methylation analysis, histone modification detection, non-coding RNA profiling, epigenetic biomarker discovery, and single-cell epigenomics. The epigenetics drugs and diagnostic technologies market also includes sales of histone deacetylase inhibitors, RNA-based drugs, chromatin remodeling agents and bromodomain inhibitors. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Epigenetics Drugs And Diagnostic Technologies Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on epigenetics drugs and diagnostic technologies market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for epigenetics drugs and diagnostic technologies ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The epigenetics drugs and diagnostic technologies market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Technology: Deoxyribonucleic Acid (DNA) Methylation; Histone Methylation; Histone Acetylation; Large Non Coding Ribonucleic Acid (RNA); MicroRNA Modification; Chromatin Structures
• 2) By Application: Oncology; Solid Tumors; Liquid Tumors; Non Oncology; Inflammatory Diseases; Metabolic Diseases; Infectious Diseases; Cardiovascular Diseases; Other Applications
• 3) By End-User: Hospitals And Clinics; Diagnostic Centers; Other End Users
• Subsegments:
• 1) By Deoxyribonucleic Acid (DNA) Methylation: Methylation Inhibitors; Methylation Detection Kits; Methylation Profiling Technologies; Bisulfite Sequencing
• 2) By Histone Methylation: Histone Methyltransferase Inhibitors; Histone Demethylase Inhibitors; Histone Methylation Assays; Chromatin Immunoprecipitation (ChIP) Techniques
• 3) By Histone Acetylation: Histone Acetyltransferase Inhibitors; Histone Deacetylase Inhibitors (HDACi); Acetylation Detection Kits; Western Blotting for Acetylation
• 4) By Large Non-Coding Ribonucleic Acid (RNA): lncRNA Expression Profiling; lncRNA Modulation Technologies; lncRNA Detection Kits; Bioinformatics Tools for lncRNA Analysis
• 5) By MicroRNA Modification: MicroRNA Mimics; MicroRNA Inhibitors; MicroRNA Expression Analysis; MicroRNA Detection Assays
• 6) By Chromatin Structures: Chromatin Remodeling Agents; Chromatin Accessibility Assays; 3D Chromatin Architecture Technologies; Nuclear Imaging Techniques
• Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche Ltd.; Merck & Co Inc.; Novartis AG; Bristol-Myers Squibb Company
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Epigenetics Drugs And Diagnostic Technologies Market Characteristics

3. Epigenetics Drugs And Diagnostic Technologies Market Trends And Strategies

4. Epigenetics Drugs And Diagnostic Technologies Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Epigenetics Drugs And Diagnostic Technologies Growth Analysis And Strategic Analysis Framework

• 5.1. Global Epigenetics Drugs And Diagnostic Technologies PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Epigenetics Drugs And Diagnostic Technologies Market Growth Rate Analysis
• 5.4. Global Epigenetics Drugs And Diagnostic Technologies Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Epigenetics Drugs And Diagnostic Technologies Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Epigenetics Drugs And Diagnostic Technologies Total Addressable Market (TAM)

6. Epigenetics Drugs And Diagnostic Technologies Market Segmentation

• 6.1. Global Epigenetics Drugs And Diagnostic Technologies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Deoxyribonucleic Acid (DNA) Methylation
• Histone Methylation
• Histone Acetylation
• Large Non Coding Ribonucleic Acid (RNA)
• MicroRNA Modification
• Chromatin Structures
• 6.2. Global Epigenetics Drugs And Diagnostic Technologies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oncology
• Solid Tumors
• Liquid Tumors
• Non Oncology
• Inflammatory Diseases
• Metabolic Diseases
• Infectious Diseases
• Cardiovascular Diseases
• Other Applications
• 6.3. Global Epigenetics Drugs And Diagnostic Technologies Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals And Clinics
• Diagnostic Centers
• Other End Users
• 6.4. Global Epigenetics Drugs And Diagnostic Technologies Market, Sub-Segmentation Of Deoxyribonucleic Acid (DNA) Methylation, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Methylation Inhibitors
• Methylation Detection Kits
• Methylation Profiling Technologies
• Bisulfite Sequencing
• 6.5. Global Epigenetics Drugs And Diagnostic Technologies Market, Sub-Segmentation Of Histone Methylation, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Histone Methyltransferase Inhibitors
• Histone Demethylase Inhibitors
• Histone Methylation Assays
• Chromatin Immunoprecipitation (ChIP) Techniques
• 6.6. Global Epigenetics Drugs And Diagnostic Technologies Market, Sub-Segmentation Of Histone Acetylation, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Histone Acetyltransferase Inhibitors
• Histone Deacetylase Inhibitors (HDACi)
• Acetylation Detection Kits
• Western Blotting for Acetylation
• 6.7. Global Epigenetics Drugs And Diagnostic Technologies Market, Sub-Segmentation Of Large Non-Coding Ribonucleic Acid (RNA), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• lncRNA Expression Profiling
• lncRNA Modulation Technologies
• lncRNA Detection Kits
• Bioinformatics Tools for lncRNA Analysis
• 6.8. Global Epigenetics Drugs And Diagnostic Technologies Market, Sub-Segmentation Of MicroRNA Modification, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• MicroRNA Mimics
• MicroRNA Inhibitors
• MicroRNA Expression Analysis
• MicroRNA Detection Assays
• 6.9. Global Epigenetics Drugs And Diagnostic Technologies Market, Sub-Segmentation Of Chromatin Structures, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Chromatin Remodeling Agents
• Chromatin Accessibility Assays
• 3D Chromatin Architecture Technologies
• Nuclear Imaging Techniques

7. Epigenetics Drugs And Diagnostic Technologies Market Regional And Country Analysis

• 7.1. Global Epigenetics Drugs And Diagnostic Technologies Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Epigenetics Drugs And Diagnostic Technologies Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Epigenetics Drugs And Diagnostic Technologies Market

• 8.1. Asia-Pacific Epigenetics Drugs And Diagnostic Technologies Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Epigenetics Drugs And Diagnostic Technologies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Epigenetics Drugs And Diagnostic Technologies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Epigenetics Drugs And Diagnostic Technologies Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Epigenetics Drugs And Diagnostic Technologies Market

• 9.1. China Epigenetics Drugs And Diagnostic Technologies Market Overview
• 9.2. China Epigenetics Drugs And Diagnostic Technologies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Epigenetics Drugs And Diagnostic Technologies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Epigenetics Drugs And Diagnostic Technologies Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Epigenetics Drugs And Diagnostic Technologies Market

• 10.1. India Epigenetics Drugs And Diagnostic Technologies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Epigenetics Drugs And Diagnostic Technologies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Epigenetics Drugs And Diagnostic Technologies Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Epigenetics Drugs And Diagnostic Technologies Market

• 11.1. Japan Epigenetics Drugs And Diagnostic Technologies Market Overview
• 11.2. Japan Epigenetics Drugs And Diagnostic Technologies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Epigenetics Drugs And Diagnostic Technologies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Epigenetics Drugs And Diagnostic Technologies Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Epigenetics Drugs And Diagnostic Technologies Market

• 12.1. Australia Epigenetics Drugs And Diagnostic Technologies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Epigenetics Drugs And Diagnostic Technologies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Epigenetics Drugs And Diagnostic Technologies Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Epigenetics Drugs And Diagnostic Technologies Market

• 13.1. Indonesia Epigenetics Drugs And Diagnostic Technologies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Epigenetics Drugs And Diagnostic Technologies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Epigenetics Drugs And Diagnostic Technologies Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Epigenetics Drugs And Diagnostic Technologies Market

• 14.1. South Korea Epigenetics Drugs And Diagnostic Technologies Market Overview
• 14.2. South Korea Epigenetics Drugs And Diagnostic Technologies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Epigenetics Drugs And Diagnostic Technologies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Epigenetics Drugs And Diagnostic Technologies Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Epigenetics Drugs And Diagnostic Technologies Market

• 15.1. Western Europe Epigenetics Drugs And Diagnostic Technologies Market Overview
• 15.2. Western Europe Epigenetics Drugs And Diagnostic Technologies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Epigenetics Drugs And Diagnostic Technologies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Epigenetics Drugs And Diagnostic Technologies Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Epigenetics Drugs And Diagnostic Technologies Market

• 16.1. UK Epigenetics Drugs And Diagnostic Technologies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Epigenetics Drugs And Diagnostic Technologies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Epigenetics Drugs And Diagnostic Technologies Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Epigenetics Drugs And Diagnostic Technologies Market

• 17.1. Germany Epigenetics Drugs And Diagnostic Technologies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Epigenetics Drugs And Diagnostic Technologies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Epigenetics Drugs And Diagnostic Technologies Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Epigenetics Drugs And Diagnostic Technologies Market

• 18.1. France Epigenetics Drugs And Diagnostic Technologies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Epigenetics Drugs And Diagnostic Technologies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Epigenetics Drugs And Diagnostic Technologies Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Epigenetics Drugs And Diagnostic Technologies Market

• 19.1. Italy Epigenetics Drugs And Diagnostic Technologies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Epigenetics Drugs And Diagnostic Technologies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Epigenetics Drugs And Diagnostic Technologies Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Epigenetics Drugs And Diagnostic Technologies Market

• 20.1. Spain Epigenetics Drugs And Diagnostic Technologies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Epigenetics Drugs And Diagnostic Technologies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Epigenetics Drugs And Diagnostic Technologies Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Epigenetics Drugs And Diagnostic Technologies Market

• 21.1. Eastern Europe Epigenetics Drugs And Diagnostic Technologies Market Overview
• 21.2. Eastern Europe Epigenetics Drugs And Diagnostic Technologies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Epigenetics Drugs And Diagnostic Technologies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Epigenetics Drugs And Diagnostic Technologies Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Epigenetics Drugs And Diagnostic Technologies Market

• 22.1. Russia Epigenetics Drugs And Diagnostic Technologies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Epigenetics Drugs And Diagnostic Technologies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Epigenetics Drugs And Diagnostic Technologies Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Epigenetics Drugs And Diagnostic Technologies Market

• 23.1. North America Epigenetics Drugs And Diagnostic Technologies Market Overview
• 23.2. North America Epigenetics Drugs And Diagnostic Technologies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Epigenetics Drugs And Diagnostic Technologies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Epigenetics Drugs And Diagnostic Technologies Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Epigenetics Drugs And Diagnostic Technologies Market

• 24.1. USA Epigenetics Drugs And Diagnostic Technologies Market Overview
• 24.2. USA Epigenetics Drugs And Diagnostic Technologies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Epigenetics Drugs And Diagnostic Technologies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Epigenetics Drugs And Diagnostic Technologies Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Epigenetics Drugs And Diagnostic Technologies Market

• 25.1. Canada Epigenetics Drugs And Diagnostic Technologies Market Overview
• 25.2. Canada Epigenetics Drugs And Diagnostic Technologies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Epigenetics Drugs And Diagnostic Technologies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Epigenetics Drugs And Diagnostic Technologies Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Epigenetics Drugs And Diagnostic Technologies Market

• 26.1. South America Epigenetics Drugs And Diagnostic Technologies Market Overview
• 26.2. South America Epigenetics Drugs And Diagnostic Technologies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Epigenetics Drugs And Diagnostic Technologies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Epigenetics Drugs And Diagnostic Technologies Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Epigenetics Drugs And Diagnostic Technologies Market

• 27.1. Brazil Epigenetics Drugs And Diagnostic Technologies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Epigenetics Drugs And Diagnostic Technologies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Epigenetics Drugs And Diagnostic Technologies Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Epigenetics Drugs And Diagnostic Technologies Market

• 28.1. Middle East Epigenetics Drugs And Diagnostic Technologies Market Overview
• 28.2. Middle East Epigenetics Drugs And Diagnostic Technologies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Epigenetics Drugs And Diagnostic Technologies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Epigenetics Drugs And Diagnostic Technologies Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Epigenetics Drugs And Diagnostic Technologies Market

• 29.1. Africa Epigenetics Drugs And Diagnostic Technologies Market Overview
• 29.2. Africa Epigenetics Drugs And Diagnostic Technologies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Epigenetics Drugs And Diagnostic Technologies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Epigenetics Drugs And Diagnostic Technologies Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Epigenetics Drugs And Diagnostic Technologies Market Competitive Landscape And Company Profiles

• 30.1. Epigenetics Drugs And Diagnostic Technologies Market Competitive Landscape
• 30.2. Epigenetics Drugs And Diagnostic Technologies Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck & Co Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis

31. Epigenetics Drugs And Diagnostic Technologies Market Other Major And Innovative Companies

• 31.1. Thermo Fisher Scientific Inc.
• 31.2. AstraZeneca PLC
• 31.3. Illumina Inc.
• 31.4. QIAGEN NV
• 31.5. Exact Sciences Corporation
• 31.6. Abcam PLC
• 31.7. Syndax Pharmaceuticals Inc.
• 31.8. Astex Pharmaceuticals Inc.
• 31.9. Diagenode LLC
• 31.10. Cisbio Bioassays
• 31.11. 4SC AG
• 31.12. Verogen Inc.
• 31.13. Watchmaker Genomics Inc.
• 31.14. Oryzon Genomics SA
• 31.15. Cell Centric Ltd.

32. Global Epigenetics Drugs And Diagnostic Technologies Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Epigenetics Drugs And Diagnostic Technologies Market

34. Recent Developments In The Epigenetics Drugs And Diagnostic Technologies Market

35. Epigenetics Drugs And Diagnostic Technologies Market High Potential Countries, Segments and Strategies

• 35.1 Epigenetics Drugs And Diagnostic Technologies Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Epigenetics Drugs And Diagnostic Technologies Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Epigenetics Drugs And Diagnostic Technologies Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer